Unique effects of mycophenolate mofetil on cord blood T cells: Implications for GVHD prophylaxis

Transplantation

Volumn 97, Issue 8, 2014, Pages 870-878

  Derniame, Sophie ^a   Lee, Fuiyee ^a   Domogala, Anna ^a   Madrigal, Alejandro ^a   Saudemont, Aurore ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cord blood; Cyclosporin A; Hematopoietic stem cell transplantation; Mycophenolate mofetil; T cells

Indexed keywords

ANTIGENS, CD; ANTIGENS, CD45; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; CELL DEATH; CELL PROLIFERATION; CORD BLOOD STEM CELL TRANSPLANTATION; CYCLOSPORINE; CYTOKINES; FETAL BLOOD; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LECTINS, C-TYPE; LYMPHOCYTE ACTIVATION; MYCOPHENOLIC ACID; T-LYMPHOCYTES, REGULATORY;

EID: 84899475213     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000438203.19595.3f     Document Type: Article

References (50)

1. Smith AR, Wagner JE. Alternative haematopoietic stem cell sourcesfor transplantation: place of umbilical cord blood. Br J Haematol2009; 147: 246.
2. Wagner JE, Rosenthal J, Sweetman R, et al. Successful transplantationof HLA-matched and HLA-mismatched umbilical cord blood fromunrelated donors: analysis of engraftment and acute graft-versus-hostdisease. Blood 1996; 88: 795.
3. Rocha V, Labopin M, Sanz G, et al. Transplants of umbilical-cordblood or bone marrow from unrelated donors in adults with acuteleukemia. N Engl J Med 2004; 351: 2276.
4. Laughlin MJ, Eapen M, Rubinstein P, et al. Outcomes after transplantationof cord blood or bone marrow from unrelated donors inadults with leukemia. N Engl J Med 2004; 351: 2265.
5. Shlomchik WD. Graft-versus-host disease. Nat Rev Immunol 2007; 7: 340.
6. Holler E. Risk assessment in haematopoietic stem cell transplantation:GvHD prevention and treatment. Best Pract Res Clin Haematol2007; 20: 281.
7. Ho VT, Cutler C. Current and novel therapies in acute GVHD. BestPract Res Clin Haematol 2008; 21: 223.
8. Auletta JJ, Cooke KR. Bone marrow transplantation: new approachesto immunosuppression and management of acute graft-versus-hostdisease. Curr Opin Pediatr 2009; 21: 30.
9. Zeiser R, Marks R, Bertz H, et al. Immunopathogenesis of acute graftversus-host disease: implications for novel preventive and therapeuticstrategies. Ann Hematol 2004; 83: 551.
10. Osunkwo I, Bessmertny O, Harrison L, et al. A pilot study of tacrolimusand mycophenolate mofetil graft-versus-host disease prophylaxis inchildhood and adolescent allogeneic stem cell transplant recipients. BiolBlood Marrow Transplant 2004; 10: 246.
11. Alousi AM, Weisdorf DJ, Logan BR, et al. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft- versushostdisease: a randomized phase 2 trial from the Blood and MarrowTransplant Clinical Trials Network. Blood 2009; 114: 511.
12. Nieto Y, Patton N, Hawkins T, et al. Tacrolimus and mycophenolatemofetil after nonmyeloablative matched-sibling donor allogeneic stemcelltransplantations conditioned with fludarabine and low-dose totalbody irradiation. Biol Blood Marrow Transplant 2006; 12: 217.
13. Jacobson P, Rogosheske J, Barker JN, et al. Relationship ofmycophenolicacid exposure to clinical outcome after hematopoietic cell transplantation.Clin Pharmacol Ther 2005; 78: 486.
14. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms ofaction. Immunopharmacology 2000; 47: 85.
15. Allison AC, Eugui EM. Mechanisms of action of mycophenolate mofetilin preventing acute and chronic allograft rejection. Transplantation 2005;80(2 Suppl): S181.
16. Villarroel MC, Hidalgo M, Jimeno A. Mycophenolate mofetil: Anupdate. Drugs Today (Barc) 2009; 45: 521.
17. Bolwell B, Sobecks R, Pohlman B, et al. A prospective randomizedtrial comparing cyclosporine and short course methotrexate withcyclosporine and mycophenolate mofetil for GVHD prophylaxis inmyeloablative allogeneic bone marrow transplantation. Bone MarrowTransplant 2004; 34: 621.
18. Neumann F, Graef T, Tapprich C, et al. Cyclosporine A and mycophenolatemofetil vs cyclosporine A and methotrexate for graft-versus-host diseaseprophylaxis after stem cell transplantation from HLA-identicalsiblings. Bone Marrow Transplant 2005; 35: 1089.
19. Nash RA, Johnston L, Parker P, et al. A phase I/II study of mycophenolatemofetil in combination with cyclosporine for prophylaxis of acutegraft-versus-host disease after myeloablative conditioning and allogeneichematopoietic cell transplantation. Biol Blood Marrow Transplant2005; 11: 495.
20. Perez-Simon JA, Martino R, Caballero D, et al. Reduced- intensityconditioning allogeneic transplantation from unrelated donors: evaluationof mycophenolate mofetil plus cyclosporin A as graft-versushostdisease prophylaxis. Biol Blood Marrow Transplant 2008; 14: 664.
21. Shevach EM. The effects of cyclosporin A on the immune system.Annu Rev Immunol 1985; 3: 397.
22. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporinA and FK506. Immunol Today 1992; 13: 136.
23. Flanagan WM, Corthesy B, Bram RJ, et al. Nuclear association of aT-cell transcription factor blocked by FK-506 and cyclosporin A.Nature 1991; 352: 803.
24. Rao A, Luo C, Hogan PG. Transcription factors of the NFAT family:regulation and function. Annu Rev Immunol 1997; 15: 707.
25. D'ArenaG,Musto P, Cascavilla N, et al. Flowcytometric characterizationof human umbilical cord blood lymphocytes: immunophenotypic features.Haematologica 1998; 83: 197.
26. Szabolcs P. T-lymphocyte recovery and function after cord bloodtransplantation. Immunol Res 2011; 49: 56.
27. Godfrey WR, Spoden DJ, Ge YG, et al. Cord blood CD4(+)CD25(+)-derived T regulatory cell lines express FoxP3 protein and manifest potentsuppressor function. Blood 2005; 105: 750.
28. Han P, Hodge G, Story C, et al. Phenotypic analysis of functionalT-lymphocyte subtypes and natural killer cells in human cord blood:relevance to umbilical cord blood transplantation. Br J Haematol1995; 89: 733.
29. Nitsche A, Zhang M, Clauss T, et al. Cytokine profiles of cord and adultblood leukocytes: differences in expression are due to differences in expressionand activation of transcription factors. BMC Immunol 2007; 8: 18.
30. McDouall RM, Suitters AJ, Smith H, et al. Increased cyclosporinesensitivity of T cells from cord blood compared with those from theadult. Clin Exp Immunol 1994; 95: 519.
31. Kadereit S, Kozik MM, Junge GR, et al. Cyclosporin A effects duringprimary and secondary activation of human umbilical cord blood Tlymphocytes. Exp Hematol 2001; 29: 903.
32. Lin SJ, Kuo ML, Cheng PJ, et al. Differential cyclosporin-A sensitivityon survival and activation of umbilical cord and adult peripheralblood CD4+ T cells. Transpl Immunol 2007; 18: 172.
33. Furukawa T, Kurasaki-Ida T, Masuko M, et al. Pharmacokinetic andpharmacodynamic analysis of cyclosporine A (CsA) to find the bestsingle time point for the monitoring and adjusting of CsA dose usingtwice-daily 3-h intravenous infusions in allogeneic hematopoieticstem cell transplantation. Int J Hematol 2010; 92: 144.
34. Cattaneo D,Merlini S, Zenoni S, et al. Influence of co-medication withsirolimus or cyclosporine on mycophenolic acid pharmacokinetics inkidney transplantation. Am J Transplant 2005; 5: 2937.
35. Jeong H, Kaplan B. Therapeutic monitoring of mycophenolate mofetil.Clin J Am Soc Nephrol 2007; 2(1): 184.
36. Bremer S, Vethe NT, Rootwelt H, et al. Expression of IMPDH1 is regulatedin response to mycophenolate concentration. Int Immunopharmacol2009; 9: 173.
37. Bremer S, Vethe NT, Rootwelt H, et al. Mycophenolate pharmacokineticsand pharmacodynamics in belatacept treated renal allograftrecipientsVa pilot study. J Transl Med 2009; 7: 64.
38. Harris DT, Schumacher MJ, Locascio J, et al. Phenotypic and functionalimmaturity of human umbilical cord blood T lymphocytes.Proc Natl Acad Sci USA 1992; 89: 10006.
39. Hodge MR, Ranger AM, Charles de la Brousse F, et al. Hyperproliferationand dysregulation of IL-4 expression in NF-ATp-deficient mice.Immunity 1996; 4: 397.
40. Klingebiel T, Schlegel PG. GVHD: overview on pathophysiology, incidence,clinical and biological features. Bone Marrow Transplant1998;21(Suppl 2): S45.
41. Holler E, Kolb HJ, Hintermeier-Knabe R, et al. Role of tumor necrosisfactor alpha in acute graft-versus-host disease and complicationsfollowing allogeneic bone marrow transplantation. Transplant Proc1993; 25(1 Pt 2): 1234.
42. Mercier-Letondal P, Montcuquet N, Sauce D, et al. Alloreactivity of exvivo-expanded T cells is correlated with expansion and CD4/CD8ratio. Cytotherapy 2008; 10: 275.
43. Ukena SN, Velaga S, Geffers R, et al. Human regulatory T cells in allogeneicstem cell transplantation. Blood 2011; 118: e82.
44. Brunstein CG, Miller JS, Cao Q, et al. Infusion of ex vivo expanded Tregulatory cells in adults transplanted with umbilical cord blood:safety profile and detection kinetics. Blood 2011; 117: 1061.
45. Di Ianni M, Falzetti F, Carotti A, et al. Tregs prevent GVHD andpromote immune reconstitution in HLA-haploidentical transplantation.Blood 2011; 117: 3921.
46. Demirkiran A, Sewgobind VD, van der Weijde J, et al. Conversionfrom calcineurin inhibitor to mycophenolate mofetil-based immunosuppressionchanges the frequency and phenotype of CD4+FOXP3+regulatory T cells. Transplantation 2009; 87: 1062.
47. Fourtounas C, Dousdampanis P, Sakellaraki P, et al. Different immunosuppressivecombinations on T-cell regulation in renal transplantrecipients. Am J Nephrol 2010; 32: 1.
48. Lopez-Cabrera M, Santis AG, Fernandez-Ruiz E, et al. Molecularcloning, expression, and chromosomal localization of the humanearliest lymphocyte activation antigen AIM/CD69, a new member ofthe C-type animal lectin superfamily of signal-transmitting receptors.J Exp Med 1993; 178: 537.
49. McGoldrick SM, Bleakley ME, Guerrero A, et al. CytomegalovirusspecificT cells are primed early after cord blood transplant but fail tocontrol virus in vivo. Blood 2013; 121: 2796.
50. Ritter ML, Pirofski L. Mycophenolate mofetil: effects on cellular immunesubsets, infectious complications, and antimicrobial activity.Transpl Infect Dis 2009; 11: 290.